Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Total 13F shares
-
2,274,870
-
Share change
-
-533,838
-
Total reported value
-
$1,294,095
-
Price per share
-
$0.57
-
Number of holders
-
23
-
Value change
-
-$331,488
-
Number of buys
-
5
-
Number of sells
-
12
Institutional Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q2 2022
As of 30 Jun 2022,
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,274,870 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, COMMONWEALTH EQUITY SERVICES, LLC, HighMark Wealth Management LLC, FRANKLIN RESOURCES INC, Raymond James Financial Services Advisors, Inc., and NORTHERN TRUST CORP.
This page lists
23
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.